Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis.

Stein, Jürgen; Haas, Jennifer Scarlet; Ong, Siew Hwa; Borchert, Kathrin; Hardt, Thomas; Lechat, Elmira; Nip, Kerry; Foerster, Douglas; Braun, Sebastian; Baumgart, Daniel C

Stein, Jürgen; Haas, Jennifer Scarlet; Ong, Siew Hwa; Borchert, Kathrin; Hardt, Thomas; Lechat, Elmira; Nip, Kerry; Foerster, Douglas; Braun, Sebastian; Baumgart, Daniel C.

Afiliação

Stein J; Interdisciplinary Crohn Colitis Center Rhein-Main, Frankfurt/Main, Germany.
Haas JS; Department of Gastroenterology and Clinical Nutrition, DGD Clinics Sachsenhausen, Teaching Hospital of the J.W. Goethe University, Frankfurt/Main, Germany.
Ong SH; Xcenda GmbH, Hannover, Germany.
Borchert K; Vifor Pharma Ltd., Glattbrugg, Switzerland.
Hardt T; Xcenda GmbH, Hannover, Germany.
Lechat E; Vifor Pharma Deutschland GmbH, Munich, Germany.
Nip K; Vifor Pharma Ltd., Glattbrugg, Switzerland.
Foerster D; Vifor Pharma Deutschland GmbH, Munich, Germany.
Braun S; Vifor Pharma Ltd., Glattbrugg, Switzerland.
Baumgart DC; Xcenda GmbH, Hannover, Germany.

Clinicoecon Outcomes Res ; 10: 93-103, 2018.

Article em En | MEDLINE | ID: mdl-29440920

Palavras-chave

Germany; claims data; health care cost; inflammatory bowel disease; iron treatment; iron-deficiency anemia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Agentes_cancerigenos Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google